PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Esteva, Francisco J., Guo, Hua, Zhang, Siyuan, Santa-Maria, Cesar, Stone, Steven, Lanchbury, Jerry S., Sahin, Aysegul A., Hortobagyi, Gabriel N. +1 more·2010·The American Journal of Pathology

DOI 10.2353/ajpath.2010.090885

Cited by (285)

Items 201–285 of 285

De Novo Resistance Biomarkers to Anti-Her2 Therapies in Her2-Positive Breast Cancer
Adela Madrid-Paredes, Marisa Cañadas‐Garre, Antonio Sánchez–Pozo, Miguel Ángel Calleja‐Hernández · 2015 · Pharmacogenomics
Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
Kai Yuan, Hongyan Wu, YULONG WANG, Hongqiang Chen, Mingwen Jiao, Rongzhan Fu · 2014 · Oncology Letters
Primary systemic therapy in HER2-amplified breast cancer: a clinical review
Mustafa Khasraw, Richard H. Bell · 2012 · Expert Review of Anticancer Therapy
Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors
Qingfei Wang, Hui Ding, Baorui Liu, Shau-Hsuan Li, Ping Li, Hailiang Ge, Kui Zhang · 2014 · International Journal of Oncology
Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab
Heena Singla, Raman Preet Kaur, Gowhar Shafi, Rajesh Vashistha, Raja Paramjeet Singh Banipal, Vinod Kumar, Anjana Munshi · 2018 · Molecular Biology Reports
Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study
Zhanhong Chen, Yabing Zheng, Wen‐Ming Cao, Yuzi Zhang, Zhengyi Zhao, Guoqiang Wang, Jing Zhao, Shangli Cai, Xiying Shao, Jian Huang et al. · 2019 · Cancer Medicine
HER2 Signaling in Breast Cancer
Incheol Shin · 2021 · Advances in experimental medicine and biology
FBXL10 contributes to the progression of nasopharyngeal carcinoma via involving in PI3K/mTOR pathway
Yaoyao Ren, Long Wu, Xuelian Li, W. LI, Yonggong Yang, Min Zhang · 2015 · Neoplasma
Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance
Gerjon J. Ikink, Mandy Boer, Elvira R. M. Bakker, Annabel Vendel-Zwaagstra, Chris Klijn, Jelle ten Hoeve, Jos Jonkers, Lodewyk F.A. Wessels, John Hilkens · 2018 · Oncogene
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
Mark M. Moasser · 2022 · Cancer Research
Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey W. Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao et al. · 2020 · Molecular Cancer Research
Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Defne Yarar, Johanna Lahdenranta, William Kubasek, Ulrik B. Nielsen, Gavin MacBeath · 2015 · Molecular Cancer Therapeutics
The prognostic value of phosphatase and tensin homolog negativity in breast cancer: A systematic review and meta-analysis of 32 studies with 4393 patients
Zu‐Yao Yang, Yuan-Yuan Yu, Jin-Qiu Yuan, Wei-Xi Shen, Dayong Zheng, Jinzhang Chen, Chen Mao, Jin-Ling Tang · 2016 · Critical Reviews in Oncology/Hematology
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Ingrid A. Mayer · 2015 · Current Breast Cancer Reports
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
Bing Sun, Lijuan Ding, Shikai Wu, Santai Song, Xiangying Meng · 2016 · OncoTargets and Therapy
Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer
Ebubekir Dirican, Mustafa Akkіprіk · 2017 · Tumor Biology
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
Renata Duchnowska, for the Central and East European Oncology Group (CEEOG), Piotr Jan Wysocki, Konstanty Korski, Bogumiła Czartoryska-Arłukowicz, Anna Niwińska, Marlena Orlikowska, Barbara S. Radecka, Maciej Studziński, Regina Demlová et al. · 2015 · Oncotarget
Gastric Carcinoma: Morphologic Classifications and Molecular Changes
Sunmi Lee, Kyoung‐Mee Kim, Jae Yoon Ro · 2013 · InTech eBooks
Immunohistochemistry for PTEN testing in HR +/HER2˗ metastatic breast cancer
Nicola Fusco, Elena Guerini-Rocco, Isabella Castellano, Umberto Malapelle · 2025 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions
Mohsin Soleja, Mothaffar Fahed Rimawi · 2016 · Current Problems in Cancer
Effect of trastuzumab on Notch-1 signaling pathway in breast cancer SK-BR3 cells
Ming Han, Huayu Deng, Rong Jiang · 2012 · Chinese Journal of Cancer Research
Expression of PTEN‑long nephritis and its effect on renal inflammation
Hui Wang, Qingxia Yu, Lin Wang, Yongwei Li, Mao Xie, Youyi Lu, Yupeng Cui · 2018 · Experimental and Therapeutic Medicine
Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis
Diana E. Ramirez-Ardila, A. Mieke Timmermans, Jean Helmijr, John W.M. Martens, Els M.J.J. Berns, Maurice P.H.M. Jansen · 2017 · Translational Oncology
PIK3CA: a Target or a Marker in Breast Cancers
Maria Vittoria Dieci, Valentina Guarneri · 2015 · Current Breast Cancer Reports
PTEN loss is not associated with trastuzumab resistance in metastatic breast cancer.
Muharrem Kocar, Emine Baş Bozkurtlar, Ferhat Telli, Nazım Serdar Turhal, Handan Kaya, Hande Kocar, Fulden Yumuk · 2014 · PubMed
Identifying Responders to Trastuzumab Therapy in Breast Cancer
Anja Høegh Brügmann, Boe Sandahl Sørensen · 2011 · Future Oncology
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
Benjamin C. Calhoun, Bryce Patrick Portier, Zhen Wang, Eugen C. Minca, George Thomas Budd, Christopher P. Lanigan, Raymond R. Tubbs, Larry E. Morrison · 2016 · BMC Cancer
Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients
Giancarlo Pruneri, Giuseppina Bonizzi, Andrea Vingiani · 2016 · Current Opinion in Oncology
Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer
Lingfei Wang, Xiaojie Yu, Jian Dong, Yanchun Meng, Yang� Yang, Huajing Wang, Chao Wang, Yajun Zhang, Yirong Zhao, Jian Zhao et al. · 2016 · Biochemical and Biophysical Research Communications
Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics
Rie Horii, Masaaki Matsuura, Shingo Dan, Masaru Ushijima, Natsue Uehiro, Akiko Ogiya, Naoko Honma, Yoshinori Ito, Takuji Iwase, Takao Yamori et al. · 2014 · International Journal of Clinical Oncology
Biomarkers for Predicting Response to Anti- HER2 Agents
Vinay Varadan, María L. Sandoval, Lyndsay N. Harris · 2016 · Advances in experimental medicine and biology
HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity
Céline André, Aurélie Bertaut, Sylvain Ladoire, Isabelle Desmoulins, Clémentine Jankowski, Françoise Beltjens, Céline Charon‐Barra, Anthony Bergeron, Corentin Richard, Romain Boidot et al. · 2024 · Cancers
TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer
Hideki Watanabe, Hiroshi Nakagomi, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochizuki, Masayuki Inoue, Ayako Kimura, Masao Omata · 2022 · Breast Cancer Research and Treatment
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
Sung‐Bae Kim, In‐Gu Do, Janice Wing Hang Tsang, Tae‐You Kim, Yoon Sim Yap, Gerardo H. Cornelio, Gyungyub Gong, Soonmyung Paik, Suee Lee, Ting‐Ying Ng et al. · 2019 · Cancer Research and Treatment
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors
Ashish Juvekar, Gerburg M. Wulf · 2013 · Breast Cancer Research
Trastuzumab-Resistance and Breast Cancer
Milos Dokmanovic, Wen Jin · 2011 · InTech eBooks
HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies
Nandini Dey, Brian R Leyland-Jones, Pradip K. De · 2016 · Cancer drug discovery and develogment/Cancer drug discovery and development
Clinical value of isoform-specific detection and targeting of AKT1, AKT2 and AKT3 in breast cancer
Gizeh Pérez‐Tenorio, Elin A. Karlsson, Olle Stål · 2014 · Breast Cancer Management
A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.
Nandini Dey, Jennifer Carlson Aske, Xiaoqian Lin, Yuliang Sun, Brian R Leyland-Jones, Lori S. Friedman, Pradip K. De · 2021 · PubMed Central
Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Time to Step Out of the Limelight
NU Lin, Eric P. Winer · 2010 · Journal of Clinical Oncology
Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer
Rita Nahta · 2019 · Resistance to targeted anti-cancer therapeutics
Tyrosine Kinase Inhibitors
Burcu Çakar, Erdem Göker · 2019 · Springer eBooks
Signification clinique, diagnostique et intérêt théranostique des mutations du gène PIK3CA dans le cancer du sein
Alexandre Harlé, Maëva Lion, Nicolas Lozano, Jean‐Louis Merlin · 2013 · Bulletin du Cancer
Mathematical modelling of Her2 (ErbB2) PI3K/AKT signalling pathways during breast carcinogenesis to include PTPD2
Bing Ji, Jiawei Bai, Luis A. J. Mur, Mengjia Zou, Jiwan Han, Rui Gao, Qing Zhen Yang · 2020 · AIMS Mathematics
Trametinib alleviates lipopolysaccharide-induced acute kidney injury by inhibiting macrophage polarization through the PI3K/Akt pathway
Yingqi Zeng, Wenjia Yuan, Chen Feng, Longkai Peng, Xubiao Xie, Fenghua Peng, Tengfang Li, Minjie Lin, Hedong Zhang, Helong Dai · 2025 · Transplant Immunology
Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma
Jelena M. Stojšić, Tijana Stanković, Sonja Stojković, Vedrana Milinković, Jelena Dinić, Zorica C. Milosevic, Zorka Milovanović, Nikola Tanić, Jasna Banković · 2014 · Experimental and Molecular Pathology
Biweekly Combination of Trastuzumab, Docetaxel and Gemcitabine for HER2-Positive Metastatic Breast Cancer: Results of a Phase II GOIM Study
Laura Orlando, Francesco Giotta, Vito Lorusso, Ferdinando De Vita, Gianfranco Filippelli, Evaristo Maiello, Ferdinando Riccardi, Giovanni Luigi Pappagallo, Palma Fedele, Nicola Gebbia et al. · 2014 · Future Oncology
Resistance to HER2-Targeted Therapy
Dirk Theile, Gal Lenz, Jamil Antonio Momand, Susan E. Kane · 2017 · Resistance to targeted anti-cancer therapeutics
A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+ Breast Cancer
Alexandre Holzbach Júnior, Bernardo Perin Cima, Mari Dalva Staffen, Juliana Dal‐Ri Lindenau, Yara Costa Netto Muniz · 2023 · Mini-Reviews in Medicinal Chemistry
A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors
Alison M. Schram, Naoko Takebe, Anna Chen, Qin C Zhou, Alexia E. Iasonos, J. Silber, M.E. Reynolds, S. Hussain, M. Gavriliuc, Lillian Mary Smyth et al. · 2025 · ESMO Open
Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors
Qingfei Wang, Hui Ding, HAI WANG, Ping Li, Baorui Liu, Kui Zhang · 2014 · Oncology Reports
Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond
Dimitrios Zardavas, Lina Pugliano, Felipe Ades, Ivana Božović‐Spasojević, Marta Capelán, Evandro de Azambuja · 2012 · Breast Cancer Management
Are mutations in K-RAS, BRAF and PIK3CA genes critical for response to adjuvant trastuzumab treatment in patients with HER-2 positive breast cancer?
Anne Marie Bak Jylling, Anders Aamann Rasmussen, Erik Hugger Jakobsen, René dePont Christensen, Flemming Brandt Sørensen · 2014 · journal of cancer therapeutics and research
Two-Temperature Formalin Fixation Preserves Activation States Efficiently
David R. Chafin · 2015 · Recent results in cancer research/Recent Results in Cancer Research
68Ga-DTPA Anti-HER2 positron emission tomography/CT successfully predicts the overexpression of human epidermal growth factor receptor in lung metastases from breast cancer
Quetzali Pitalúa-Cortés, Francisco O. García-Pérez, Yolanda Villaseñor‐Navarro, Fernando Ulises Lara-Medina, Juan Antonio Matus-Santos, Irma Soldevilla-Gallardo, Fany Iris Porras-Reyes, Víctor M. Pérez-Sánchez, Héctor Aquiles Maldonado-Martínez, Wendy B. Pérez-Báez et al. · 2017 · BJR|case reports
The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer
Chi Zhang, Ying Guo, Jiyu Li, Xingsong Tian, Xuening Duan · 2019 · Medicine
Evaluation of PIK3CA Gene Mutations in Breast Cancer Patients Treated by Trastuzumab
Elahe Nazeri, Mohammad Parniani, Asiie Olfatbakhsh, Safa Najafi, Marzieh Peyman, Behzad Karami, Sina Halvaei, Rezvan Esmaeili · 2023 · Archives of Breast Cancer
The Role of Phosphoinositide 3-Kinase in Breast Cancer: An Overview
Patricia Mucci LoRusso, Scott Anthony Boerner · 2010 · Clinical Breast Cancer
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
Francisco J. Esteva · 2014 · Breast Diseases A Year Book Quarterly
Development of a machine learning model for predicting the expression of proteins associated with targeted therapy in endometrial cancer
Chenwen Sun, Qianling Li, Yanan Huang, Yang Xia, M P Li, Xiucong Zhu, Jinke Zhu, Zhenhua Zhao · 2026 · Frontiers in Oncology
PIK3CA Oncogenic Mutations in Neoadjuvant Treatments for Breast Cancer
Giovanni Corso, Paolo Veronesi, Mattia Intra, Virgilio Sacchini, Viviana Enrica Galimberti · 2017 · Biomarkers in Medicine
HER2 pozitif metastatik meme kanserinde PTEN, P27 ve PI3K ekspresyonunun prediktif ve prognostik önemi
Sadi Kerem Okutur · 2011 · Istanbul Science University (Istanbul Bilim University)
Participación del factor de necrosis tumoral alfa en la proliferación de carcinomas mamarios
Martín A. Rivas · 2010 · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing
Xiaoping Su, Gabriel G. Malouf, Francisco J. Esteva · 2013 · Springer eBooks
Determining the Role of Autophagy in HER2/neu-Induced Mammary Tumor Dormancy and Recurrence
Samantha Dwyer · 2013 · Scholarly Commons (University of Pennsylvania)
Inmunofenotipos de cáncer de mama en pacientes jovenes (40 años o menores): estudio de la expresión inmunohistoquímica de la vía IGF1R, PTEN/Akt/mTOR
María Planelles Asensio · 2015 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Estudio de adecuación de la prescripción de quimioterapia en cáncer de mama en un hospital de tercer nivel
Ana María Alañón Pardo · 2014 · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Brèves de l’AERIO
F.-G. Riet, C.-H. Canova, L. Feuvret, C. Bourgier · 2013 · ONCOLOGIE
mTOR as a target in breast cancer: the emerging role of everolimus
Michael Newton, Govardhanan Nagaiah, Jame Abraham · 2012 · Breast Cancer Management
Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs
Séverine Guiu, Bruno P. Coudert, P. Fumoleau · 2012 · Springer eBooks
Adverse reaction of a combined treatment for unresectable liver cancer
Jianjun Ren, Tao Jiang, Rui Peng · 2013 · Open Medicine
Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy
Ali Sakhdari, Lloyd Hutchinson, Ediz F. Cosar · 2015 · Molecular pathology library
Tyrosine Kinase Inhibitors
Burcu Çakar, Erdem Göker · 2016 · Springer eBooks
Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer
Roberta Ferraldeschi, Gerhardt Attard · 2011 · CRC Press eBooks
The Role of mTOR Inhibitors in Breast Cancer
Philippe Georges Aftimos, Martine J Piccart · 2015 · Springer eBooks
Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Eun-Byeol Ko, Min-Ki Seong, Hyang Suk Choi, Chan Sub Park, Ji Hye Choi, Jin‐Kyung Lee, Hyesil Seol, Hyun‐Ah Kim, Woo Chul Noh · 2017 · Journal of Breast Disease
Brèves de l’AERIO
Benjamin Verret, S. Dumont, Zahra Castel Ajgal, Johanna Wassermann · 2016 · ONCOLOGIE
Targeting the EGFR family of receptor tyrosine kinases
Siyuan Zhang, Dihua Yu · 2013 · Cambridge University Press eBooks
Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer
Roberta Ferraldeschi, Gerhardt Attard · 2011 · Informa Healthcare eBooks
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
K. Dunton, Gerard Timmy Vondeling, Elizabeth Hancock, Margaret Petrou, Oliver Burn, Abby Paine · 2022 · Targeted Oncology
Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features of PIK3CA-Mutated Breast Cancer
Jolanta Smok-Kalwat, Grzegorz Chmielewski, Rafał Stando, Jacek Sadowski, Paweł Macek, Artur Kowalik, Ewelina Nowak-Ozimek, Stanisław S. Góźdź · 2023 · Diagnostics
HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects
Hongyan Zhang, Ding Ma, Fubing Li, Zhimin Shao, Ceshi Chen · 2026 · Science China Life Sciences
HER2 in Cancer Biology and Precision Oncology: Gene Structure, Signaling Pathways and Targeted Therapeutic Strategies
Viorica Elena Radoi · 2026 · IntechOpen eBooks
Comment augmenter la performance des médicaments anti-HER?
Florence Dalenc, Yann Bergé, Henri Hubert Roche · 2012 · Springer eBooks
Novel Role of ErbB-2 in Inhibition of Jagged-1-Mediated Trans-Activation of Notch in Breast Cancer
Kinnari Pandya · 2013 · Loyola eCommons (Loyola University of Chicago)